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ABSTRACT
Sex hormone deficiency in post-menopausal women causes changes in the lower urinary tract. Vulvovaginal atrophy is 
a pathology resulting from those changes. VVA has a negative effect on the quality of life therefore prompting a search 
for new therapeutic options. The aim of this article is to summarize the current treatment modalities, both hormonal and 
non-hormonal for post-menopausal vaginal atrophy. Topical oestrogen therapy remains the “golden standard”. Alternatives, 
although promising, require well-designed control studies.
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INTRODUCTION
The post-menopausal period comprises up to 1/3 of 
a woman’s life. Diminished ovarian function has an adver-
se effect on the quality of life. Hot flushes, night sweats, 
anxiety, mood swings, irritability and sleeping disorders 
often occur [1]. Sex hormone deficiency affects changes in 
many organs including the lower urinary tract. Oestrogens 
are the main regulators of physiological functions of the 
vagina. They influence maturation, adequate thickness and 
structure of the epithelium, proper vascular flow, quality 
and structure of the collagen, low vaginal pH and vagi-
nal secretion. 40–60% of post-menopausal women suffer 
from atrophic changes of the vagina (VVA, vulvovaginal 
atrophy) [2]. These changes involve the thinning of the va-
ginal epithelium, a less prominent vaginal rugae, increased 
friability, irritation, burning and pruritus, contact bleeding 
and discomfort during sexual intercourse due to vaginal 
dryness. Moreover, decreased glycogen storage, that con-
stitutes substrate for lactic acid production by Lactobacilli, 
leads to vaginal alkalization and the dysfunction of the 
physiological bacterial flora. The described constellation of 
signs and symptoms, accompanied by urgency, dysuria and 
recurrent urinary tract infections is labeled as the genitouri-
nary syndrome of menopause (GSM) [3–5]. A multi-center, 
population study AGATA based on 913 women, mean age 
59.3, revealed the GSM prevalence in 79.1%, occurring 
1–6 years after menopause. In this observation, all women 
diagnosed with GSM suffered from vaginal dryness, 77.8% 
reported dyspareunia, whereas burning, itching and dysuria 
occurred in 56.9%, 56.6% and 36.1% respectively [6]. These 
symptoms significantly decrease the quality of life, especial-
ly in the sexual sphere, which was confirmed by the REVIVE 
study, conducted on a group of 3046 post-menopausal 
women [7]. The CLOSER study showed that dyspareunia is 
the reason for the limitation or complete withdrawal from 
sexual life which substantially disturbs partner relations 
[8, 9], and often causes depression and decreased self-
-assessment [10]. Therefore, the aim of GSM/VVA therapy 
is the restoration of proper vaginal epithelium function, 
relief from the signs and symptoms caused by sex hormone 
deficiency and improvement in the quality of life with the 
special interest in sexual life.
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AN OVERVIEW OF THE CURRENT  
TREATMENT OPTIONS
Topical oestrogen therapy
Topical vaginal oestrogens constitute the golden stan-
dard of VVA therapy. Oestrogens act on a molecular level 
by activation of the oestrogen receptors ER-alpha and ER-
-beta. ER-alpha receptors are localised in the uterus, ovaries, 
oviducts, mammary gland, hypothalamus, liver, fibroblasts 
and macrophages, while ERs-beta are found in the ovaries, 
central nervous, circulatory, immune, genitourinary and 
respiratory systems [11, 12]. Both types of receptors are 
present in the vaginal wall, but their distribution is affected 
by the menstrual status. Chen et al [13] reported the expres-
sion of ER-alpha in the vagina of premenopausal and post-
menopausal women, while ER-beta expression was found 
only in premenopausal women. These outcomes could be 
affected by a small number of the postmenopausal women 
(No-4). Gebhart et al [14] confirmed significant differences 
in the presence and expression of ER-alpha and ER-beta in 
the vaginal tissue between premenopausal and postmeno-
pausal women. In the postmenopausal women, the expres-
sion of ER-beta in the vaginal wall was detected, but it was 
markedly reduced, regardless of oestrogen therapy. There 
are two ways of oestrogen receptor stimulation, classical 
and non-classical. The classical, genomic pathway, leads 
to receptor nuclear translocation induction and binding to 
EREs (oestrogen response elements). This has a direct effect 
on DNA which regulates transcription of target gens. The 
non-classical signalling concerns the membrane-associated 
receptor activation and induction of cytoplasmic pathways 
such as PI3K/Akt, ERK and p38. The stimulation of ER by the 
non-classical way causes rapid, immediate oestrogen effect. 
So far, the mechanism of choosing classical or non-classical 
pathway remains unknown. Oestrogen receptors also affect 
the activation of growth factors, such as EGFR, HER2/Neu 
and IGFR [15–19]. Sawczuk el al. [20] showed the relation-
ship between both oestrogen receptor expression and the 
way of oestrogens administration. Local therapy caused 
higher ERs-alpha and ERs-beta density, compared to syste-
mic treatment. The study revealed, that topical oestrogen 
therapy is more effective in stimulating epithelial vaginal 
receptors. The other authors conclude, that a therapeutic 
effect is limited only to the treatment period and abates 
shortly after stopping the therapy. Moreover, oestrogens 
influence only the epithelium, causing its thickening and 
stimulating secretion, with no effect on the extracellular 
matrix and neovascularization [21]. Recently animal models 
described oestrogens effect on collagen synthesis [22]. The 
2017 Hormone Therapy Position Statement of The North 
American Menopause Society states that women with GSM 
symptoms only respond better to low-dose vaginal oestro-
gen therapy than systemic therapies. If sexual function is the 
main concern, women with menopause symptoms benefit 
from transdermal estrogen therapy (smaller effect on sex 
hormone-binding globulin and free testosterone levels) 
and from low-dose vaginal oestrogens. Moreover, in women 
without menopause symptoms systemic hormonal therapy 
does not improve sexual function [23]. One should keep 
in mind, that there are many limitations of the oestrogen 
therapy, such as hormone-dependent cancers, history of 
oestrogen-related thromboembolization and the adverse 
effects: nausea, vomiting, breast tenderness, vaginal ble-
eding but also the patient’s anxiety of cancer and cultural 
or behavioural considerations [24, 25]. There is no publi-
shed data concerning the safety of longitudinal topical 
oestrogen therapy in certain women subpopulations [26]. 
Santen [27] reported the effect of vaginally administered 
oestradiol on E2 plasma level in a dose-dependent manner. 
Low-dose vaginal oestrogen (7.5–10 µg oestradiol) incre-
ased plasma oestradiol levels but not above the normal 
range of ≤ 20 pg/mL. Surprisingly, these small increments 
were associated with systemic effects to decrease the bone 
resorption rate and to lower the serum levels of low density 
lipoprotein cholesterol. Intermediate doses (25 µg oestra-
diol) resulted in plasma levels approaching or exceeding 
20 pg/mL, while the higher doses (50–2000 µg) reached 
the premenopausal oestrogen serum levels. The amount 
of oestrogen systemically absorbed from the vagina is cli-
nically relevant with regard to an increased risk of breast 
cancer, heart disease, venothrombotic and cerebrovascular 
events. Low-dose regimens should be recommended to 
the women with atrophic vaginitis as the initial therapy 
because they are as effective in the VVA treatment as higher 
dosages. On the other hand, there is also data concerning 
the lack of efficacy of local oestrogen therapy in 23–42% 
of treated women [7]. Furthermore, the recent Cochrane 
Database systematic review on local oestrogen for vaginal 
atrophy treatment concluded, that there was low-quali-
ty evidence for the improvement of the vaginal atrophy 
symptoms in postmenopausal women, when treated with 
local oestrogen agents compared to a placebo. The authors 
found also no evidence of a difference in efficacy between 
the various topical oestrogen regimens when compared 
with each other [28]. 
LUBRICANTS AND LOCAL MOISTURISERS
This is the most popular kind of local VVA therapy. There 
are several forms of vaginal lubricants and moisturisers, such 
as globules, creams and liquids. Their main component is 
hyaluronic acid, polysaccharide, which has the ability to con-
serve a large amount of water molecules, allowing proper 
levels of moistening of the extracellular matrix. Origoni et al 
[29] assessed the effectiveness of hyaluronic acid-based li-
quid regimen for vaginal use in 46 post-menopausal women 
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during an 8-week therapy. The investigators used VAS (Visual 
Analogue Scale) to evaluate the score of the symptoms and 
VHI (Vaginal Health Index) by Gloria Bachmann [30]. VHI is 
an investigation tool clinically comprising of five vaginal 
parameters: elasticity, fluid volume, pH, epithelial integrity 
and moisture. The degree of treatment satisfaction was as-
sessed according to the Likert scale (very satisfied, satisfied, 
uncertain, dissatisfied, very dissatisfied). The study revealed 
a significant improvement in vaginal dryness, itching, bur-
ning and dyspareunia according to VAS and a 95% degree of 
patents’ satisfaction. Furthermore, an objective evaluation of 
vaginal mucosa according to VHI confirmed the subjective 
symptoms, showing statistically significant improvement of 
the mucosa quality. The obtained results are concurrent with 
the other authors’ reports, evaluating the therapeutic effect 
of the hyaluronic acid in different pharmacological forms 
and treatment modes [31–33]. Some authors point out, that 
the therapeutic effect of hyaluronic acid is limited to the 
treatment period and does not involve collagen synthesis 
and cellular maturation [34, 35]. They emphasise solely the 
symptomatic aspect of this therapy, with no influence on 
vaginal epithelium physiology. 
SELECTIVE OESTROGEN RECEPTORS 
MODULATORS
Ospemifene is the first oral non-steroid selective modu-
lator of the oestrogen receptors with the affiliation to the 
vaginal mucosa. The effectiveness of 60 mg/day ospemifene 
was assessed by Portman et al. [36] in a randomised, place-
bo-controlled, phase III trial on 314 women, who reported 
vaginal dryness as the most bothersome symptom of VVA. 
There were 33.8% responders in the treatment group com-
pared to 7.1% of patients receiving a placebo. The evaluation 
included MI (Maturation Index), vaginal pH and the severity 
of the most bothersome symptom of vaginal dryness. Si-
gnificant improvement in all assessed factors was seen in 
the treatment group during a minimum 10-week therapy. 
Adverse effects were rare although one case of deep vein 
thrombosis was noted and three patients discontinued the-
rapy due to the worsening of hot flushes. The three patients 
in the ospemifene group and one in the placebo group 
had an endometrial thickness > 5 mm after 12 weeks of 
the therapy with no pathological changes in the histology 
samples. The other randomised III phase trial evaluated 
effectiveness of ospemifene in vaginal dryness and dys-
pareunia treatment [37]. Double blind, 12-week study was 
conducted on 919 women, based on FSFI (Female Sexual 
Function Index) assessing six domains: desire, arousal and 
lubrication, orgasm, satisfaction and pain. The serum levels 
of oestradiol, FSH, LH, SHBG and testosterone were measu-
red during screening and on the final visit. In the treatment 
group, general improvement in FSFI was noticed, and was 
statistically significant for dyspareunia, with no significant 
improvement in vaginal dryness. A slight decrease of FSH 
and LH level was observed, while still in the normal limits 
for post-menopausal women. No changes in oestradiol level 
were noticed, the mean SHBG level increased, but remained 
within normal range. The total testosterone levels increased 
unremarkably in the ospemifene group, but the mean free 
testosterone level remained unchanged. The obtained data 
suggests, that the improvement confirmed by FSFI is not 
related to serum hormone changes but demonstrate the 
beneficial effect of ospemifene on vaginal mucosa. Other 
authors also described the effectiveness of ospemifene 
compared to a placebo as well as the safety of this therapy 
[38–42]. A recent review on ospemifene in the VVA treatment 
reported also that an oestrogenic effect of ospemifene on 
the bone is comparable to the bone-restoring activity of 
raloxifene. The authors highlighted an oestrogen antagoni-
stic effect of ospemifene in animal models of breast cancer 
as well as no adverse effects on the breast in clinical trials 
with postmenopausal women at 52-weeks follow-up. The 
review did not report any case of endometrial carcinoma. 
The studies demonstrated no significant risk of endometrial 
hyperplasia associated with the use of ospemifene, however 
the safety of treatment longer than 1 year is uncertain. No 
adverse effects of ospemifene on lipid profile were observed. 
The ospemifene therapy increases the risk of vein thrombo-
embolism (1.45/1000 women in the ospemifene group and 
1.04/1000 women in the placebo group), thus this treatment 
is contraindicated in women with thromboembolic disease 
or a history of these condition. Ospemifene has met the 
requirements of FDA (The Food and Drug Administration) 
for primary efficacy in vaginal atrophy and has recently been 
approved by the European Medicines Agency (EMA) to treat 
moderate-to-severe VVA in postmenopausal women who 
are not subject to local vaginal estrogen therapy [43, 44]. 
Lasofoxifene is the next drug in this group. Its affiliation to 
both types of oestrogen receptors improves vaginal secre-
tion and decreases pH. Furthermore, similar to other SERM, 
like raloxifene, lasofoxifene exerts positive effects on other 
menopausal afflictions, such as osteoporosis and coronary 
disease [5, 45]. 
Phytoestrogens are another alternative to oestro-
gens. QiBaoMeiRan (QBMR) is undergoing clinical trials, 
which is a herbal regimen originating from traditional Chi-
nese medicine. This is a mixture of the roots of: Polygoni 
Multiflori, Angelicae Sinensis, Achyrantis Bidentatae, the 
seeds of Cuscutae and the fruits of Lycii, Poria and Psora-
leae. The mechanism of action is an agonistic/antagonistic 
impact on oestrogen receptors alpha and beta, resulting 
in expression ERs-beta, which makes the QBMR act like 
SERM. The studies on animal models revealed a proliferative 
effect on the vaginal epithelium without such an impact on 
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endometrial tissue. Oestrogen acts through ERs stimulation 
including EREs pathway. QBMR therapy increases serum 
oestradiol levels with a concurrent decrease of FSH and LH 
levels. This data suggests that the effect of QBMR may be 
mediated through the hypothalamus — pituitary — ovary 
axis, which stimulates the biosynthesis of the oestrogens in 
the ovary [46]. Although the animal studies seem promising, 
the future of QBMR in the treatment of VVA in postmeno-
pausal women remains uncertain.
TOPICAL USE OF THE GROWTH FACTORS
KGF (Keratinocyte Growth Factor) cream could be a com-
petitive VVA therapy to local oestrogen administration. KGF 
is a member of the fibroblasts growth factors family (FGFs). 
It demonstrates a cytoprotective and regenerative activity, 
and deals with the maintenance of the integrity and functio-
nality of epithelial tissues. KGF acts by binding the receptor 
tyrosine kinase and probable activation of an alternative 
signalling pathway that is able to stimulate ER-alpha thro-
ugh the phosphorylation of Ser118, as well as oestradiol. 
KGF administration in the developing vagina of mice results 
in the proliferation of the vaginal epithelium, suggesting 
a potential relationship between oestrogen treatment and 
activation of KGF pathway [47, 48]. Ceccarelli et al. [49] com-
pared, an animal model in vivo and local vaginal KGF and 
E2 therapy, showing a positive impact of KGF on vaginal epi-
thelium proliferation, without systemic effects. In contrast to 
oestrogens, KGF does not affect the genomic pathway EREs, 
moreover it can prevent the activation of this pathway by 
retaining ER-alpha at the plasma membrane, thus avoiding 
its nuclear translocation. Besides, oestrogen-independent 
KGF activity, it acts on non-oestrogen-sensitive, ER-alpha 
negative cells. These observations suggest the existence 
of an overlapping between oestrogen and KGF signalling. 
Topical administration of KGF causes the recovery of vaginal 
atrophy in ovariectomized mice, thus provides a rationale 
for its pre-clinical development in humans [49]. Further 
studies are required to assess the efficiency of KGF in the 
VVA therapy in postmenopausal women.
LASER AND RADIO-FREQUENCY DEVICES  
IN VVA TREATMENT
Positive experiences with the energy transmitting devi-
ces in stimulating reparative and regenerative processes in 
tissues, prompted an interest in applying these possibilities 
in GSM therapy. 
RADIO-FREQUENCY DEVICES
Radio-frequency (RF) devices emit high frequency wa-
velengths, which meet with the tissue impedance, resulting 
in a local temperature increase. The temperature at 40–45°C 
induce synthesis of collagen by fibroblasts. These devices 
are used for nonsurgical vulvovaginal correction procedures, 
as well as for the improvement of the elasticity, tension and 
rejuvenation of the vagina. The treatment sessions are pa-
inless, well tolerable, with the duration spans of 15–30 min. 
and the patients can resume their usual activities the same 
day. In 2015, the results of treatment of vulvovaginal laxity, 
sexual dysfunction and mild to moderate stress urinary 
incontinence with RF-based device, were published [50]. 
This prospective study involved 23 women including 6 pre-
menopausal and 5 menopausal. The sessions lasted appro-
ximately 30 minutes with a working temperature range 
40–45°C. The treatment protocol consisted of three sessions 
with an interval of 4–6 weeks. There were no restrictions 
in normal patients’ activity, including sexual intercourse 
immediately after each treatment. Significant improvement 
in vaginal tightening and laxity, as well as sexual satisfaction 
and decrease in urinary incontinence were noted. Treat-
ments were well tolerated and no adverse effects were 
reported. Similar results received by Vicariotto et al. [51] 
during a twelve-months observation of 25 post-menopausal 
women with vaginal laxity and VVA/GSM-related symptoms 
treated by a low-energy dynamic quadripolar radio-frequ-
ency device. A therapeutic effect was measured according 
to VLQ (Vaginal Laxity Questionnaire), PISQ-12 (Pelvic Or-
gan Prolapse/Urinary Incontinence Sexual Questionnaire), 
SSQ (Sexual Satisfaction Questionnaire) in the vaginal laxity 
arm and VAS (Visual Analogue Scale) for the assessment of 
sexual satisfaction in the vaginal atrophy arm. Rapid and 
long-lasting improvement in both groups in all evaluated 
parameters was noted. 
LASER DEVICES IN VVA THERAPY
There are two types of lasers used in the vaginal revi-
talisation procedures: non ablative Erbium: YAG laser and 
ablative, CO2
 fractional laser. Tissue effects ranges from 
a destructive one to thermal only, depending on the laser 
energy delivered and the delivery time. 
LASER ERBIUM: YAG
Erbium:YAG is non-ablative laser, generating 2.940-nm 
wavelength that emits energy in the mid-infrared invisi-
ble light spectrum, with high absorption in water. One of 
these devices, working in “smooth” mode, produces a fast 
sequence of low-fluency laser pulses inside an overall super-
-long pulse allowing the heat to dissipate approximately 
200 µm into the mucosa, where the cumulative thermal 
effect stimulates collagen remodelling and new collagen 
synthesis. Gaspar et al. [21] compared the effectiveness of 
laser Erbium: YAG with topical estrogen in VVA treatment 
on a group of 50 post-menopausal women. The laser tre-
atment arm first received a two-week pre-treatment with 
0.5 mg oestriol ovules to improve hydro-retention of the 
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tissue. Water is a chromophore for the wavelength emitted 
by Erbium: YAG laser (the substance that absorbs photon 
energy, dispersing it as thermal energy). Then a total of 
three treatments, once every three weeks, were performed. 
The control group received an 8-week treatment of 0.5 mg 
oestriol ovules, administered daily during the first week, 
three times a week in weeks 2–4, then twice a week in weeks 
4–8. In both groups, a statistically significant reduction of 
vaginal dryness, leukorrhea, irritation and dyspareunia were 
noted, whereas in the laser arm the relief of symptoms was 
more prominent and remained at the 12–18 months follow-
-up. In the control group the therapeutic effect diminished 
at the 12-month follow up and at 18-month of observation 
some were even significantly worse than before treatment. 
After 12 months, in both groups MV (Maturity Value) of the 
epithelium improved, but in the laser arm improvement 
was much higher compared to control (52.2 and 25 points, 
respectively). Maturity Value determines the degree of the 
epithelium oestrogenisation. Oestrogenic stimulation is 
assessed by values of: 0–49 is an absence or low, 50–64 is 
medium and 65–100 is high. The pH value showed a stati-
stically significant decrease in both groups, although the 
decrease in the oestriol group was not spectacular and 
had diminished at the 12-month follow-up. A histological 
examination in the laser arm revealed an increase of the 
epithelial thickness accompanied by parakeratosis, vaso-
dilatation, improvement in vascularisation and increased 
collagenesis in the extracellular matrix. The side effects in 
both groups were transient and minimal. In the laser group, 
4% of patients reported mild-to-moderate pain and slight 
transient mucosal edema related to sensation of warmth. 
In the control group 12% experienced abdominal pain, 
8% vaginal spotting and 4% mastodynia. Similar results 
were obtained by Gambacciani et al. [52], while comparing 
Erbium: YAG laser treatment to oestrogen topical gel in 
70 post-menopausal women with VVA. Significant reduction 
of the vaginal dryness, dyspareunia and urinary inconti-
nence were noticed after a 6 month follow up. The VELAS 
(Vaginal Erbium Laser Academy Study) — an international 
multicenter observational study on the group of 1500 post-
-menopausal women is currently underway to evaluate the 
efficacy and safety of Erbium: YAG laser for the treatment of 
GSM and urinary incontinence [53].
FRACTIONAL CO2 LASER  
IN THE TREATMENT OF VVA
CO2 lasers are the members of the ablative lasers family. 
They emit wavelengths of 10.600 nm that cause thermal 
micro-damage of only a small fraction of the epithelium, 
leaving the rest of the intervening area unaltered. Minor 
affiliation to water of the CO2 laser, as compared to Erbium: 
YAG laser, and ablation of the tissue allows the delivery of 
energy deeply into epithelium. Producers created various 
shapes of energy pulses. One of them is designed especially 
for the treatment of the vaginal mucosa. The shape of this 
pulse is divided into two distinct areas. The aim of the first 
impulse, set at 60 µs, is to perform a vaporisation of the 
water-deficient and poor heat conducting epithelium. This 
impulse opens the way for the second one, lasting from 
100 to 2000 µs, with a peak power between 3 and 40 W, that 
transfer a suitable thermal energy to the connective tissue 
in order to stimulate the reparative process. The damage of 
the epithelium constitutes of evenly spread points, 200 µm 
each, covering only 6% of the tissue. Pitsouni et al. [54] 
evaluated the efficacy of CO2 laser — SmartXide
2V2LR, in 
the treatment of GSM on the group of 53 post-menopausal 
women. Signs and symptoms, such as dyspareunia, vaginal 
dryness, itching, burning and dysuria, urgency, frequency 
and general sexual satisfaction were analysed using Visual 
Analogue Scale. The efficiency of laser therapy of LUTS (Lo-
wer Urinary Tract Symptoms) was assessed using ICIQ (In-
ternational Consultation on Incontinence Questionnaires). 
The patients also fulfilled KHQ (King’s Health Questionnaire), 
UDI-6 (Urogenital Distress Inventory) and PGI-I (Patients 
Global Impression of Improvement), evaluating general 
satisfaction at the end of the study. Additionally, vaginal 
pH, MI and MV were analysed. Clinical assessment of the 
vaginal mucosa was evaluated using VHI score. All qu-
estionnaires revealed a significant reduction of VVA and 
LUT symptoms at the 12-week follow up. A significant re-
duction of symptoms or total remission reported 85% of 
patients. 27/30 women with a history of frequency above 
9 micturition/day experienced significant improvement. 
The frequency of sexual intercourse/month increased from 
a mean 1.6 to 4.1. An increase of MV and VHI is a subject of 
special interest. At the 12-week follow up, 57% and 89% of 
the participants overpassed the threshold MV > 49% and 
89% VHI > 15, respectively, with none presenting such re-
sults at the baseline. This data indicates the oestrogen-like 
effect of CO2 laser on vaginal mucosa, regardless of the time 
of menopause. This conclusion was reflected in the Vaginal 
Health Index. Vaginal atrophy remission was observed in 
47 participants. Furthermore, PGI-I revealed 90% high satis-
faction of the treatment. The authors pointed out, that it was 
difficult to identify factors predicting which women could 
benefit the best from CO2 — laser therapy. Similar results 
were obtained by Siliquini et al. [55] in a 15-month follow-
-up of 87 post-menopausal women and Behnia-Willison et 
al. [56] in a 12-month observation of 102 women with GSM 
symptoms. The participants were treated with the fractional 
CO2 laser — SmartXide
2V2LR, across a series of sessions 
performed at intervals of six or more weeks. The data was 
gathered using the Australian Pelvic Floor Questionnaire, 
which integrated bladder, bowel, sexual function, pelvic 
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organ prolapse, severity, bothersome and condition-speci-
fic quality of life. The reduction of GSM symptoms in 84% 
of patients was noted. 39.5% of the participants reported 
improvement of sexual function at the 12–24 month follow 
up. Moreover, significant improvement was observed as far 
as pelvic organ prolapse, vaginal secretion, bladder func-
tion and urgency were concerned. Complications were rare 
with slight clinical significance: three women experienced 
post-coital urinary tract infections, two reported vaginal 
discharge, three women experienced lower pelvic pain, one 
had genital herpes and finally two women presented post-
menopausal bleeding (benign in endometrial biopsies). The 
described clinical observations were confirmed by Zerbinati 
et al. [57] in a histological evaluation of the vaginal biopsies 
using light and electron microscopy. The study was conduc-
ted on a group of 50 post-menopausal women presenting 
GSM symptoms with CO2 laser — SmartXide
2V2LR. Vaginal 
biopsy was performed at the baseline, as well as after 30 and 
60 days of treatment. The investigation revealed spectacular 
changes in the vaginal mucosa. A thicker epithelium with 
a basal layer of proliferating cells and a significant storage 
of glycogen in the cells forming the intermediate and su-
perficial layer indicating a restored mechanism oriented to 
the synthesis of glycogen was noted. Additionally, a high 
degree of exfoliation with superficial cells was observed. 
A light microscopy examination revealed a rich content of 
blood vessels in the connective tissue penetrating the new-
ly-formed papillae, supporting the activity of fibroblasts. An 
ultrastructural investigation of the cells showed extended 
rough endoplasmic reticulum and vesicles for the synthesis 
and storage of procollagen molecules as well as a well-de-
veloped Golgi apparatus with associated vesicles for the 
glycosylation of proteins for the production of components 
of the extracellular matrix. To sum up, CO2-fractional laser 
therapy causes vaginal rejuvenation with structural changes 
specific for childbearing age with no need for hormonal tre-
atment. A very interesting meta-analysis was performed by 
Pitsouni et al. [58]. The authors, based on 14 trials including 
laser treatment of 542 women, demonstrated reduction 
of all GSM symptoms. However, due to heterogeneity of 
treated populations, differences in diagnoses and different 
treatment protocols, the quality of evidence was “low” or 
“very low”. In the authors’ conclusion, although laser the-
rapy seems promising, currently, evidence-based change 
in clinical practice for the management of GSM cannot be 
proposed. Well-designed controlled studies with standardi-
sed laser settings and therapeutic protocols are necessary. 
There currently are several possibilities of GSM treat-
ment available. Topical oestrogen treatment constitutes 
“the golden standard”, based on the pathophysiology of 
this affliction. A well conducted treatment should be per-
sonalised to achieve an optimal effect with reduction of 
the complications. Hormonal treatment is not suitable for 
every patient. Nowadays, non-hormonal treatment options, 
such as local creams and gels as well as RF-based and laser 
devices are performed. Some of these therapies produce 
more spectacular and long-lasting results compared to hor-
monal treatment and the hormone-like effect in the vaginal 
mucosa obtained by physical factors is also fascinating. 
It seems advisable to conduct more studies concerning 
vaginal physiology and biostructure, in order to optimise 
GSM therapy and improve the quality of life of the post-
-menopausal women. 
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